• Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types
• Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information across the continuum of cancer care.

An individual patient’s cancer is complex, with response to medicines being determined by multiple factors, including specific driver mutations from the cancer, previous therapies and acquired resistance to those therapies. The creation of a joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma collaborators to better interpret disease biology and identify drivers and timing of tumor evolution as well as intrinsic and acquired resistance mechanisms. These are critical insights with causal associations that can guide the design of clinical trials and effective therapeutics. Through this collaboration, biopharmaceutical company partners can now leverage the joint dataset, combined analytics capability, AI SaaS solutions and precision oncology footprint of ConcertAI and Guardant Health.

“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies. It represents another milestone in Guardant’s mission to conquer cancer with data.”

The integrated data offering will be unique in the industry in that it will include methylation data from biomarker tests run on the Guardant Infinity smart liquid biopsy platform, which includes an extensive methylome panel that helps identify the unique methylation pattern that each tumor comprises. This provides an important new dimension of research insights that has been largely unexplored in clinical development to date. The dataset will also be unique in that it includes genomic profiling data across the continuum of cancer care, from monitoring for residual disease and recurrence in early-stage cancer to treatment selection and therapy response monitoring in advanced cancer.

“By integrating ConcertAI’s extensive clinical dataset and enterprise AI with the new data on tumor methylation patterns enabled by Guardant Health’s innovative sequencing technology, we can partner with biopharma researchers to enable novel approaches to cancer therapy discovery, clinical study design, and innovative models for clinical development,” said Jeff Elton, Ph.D., MBA, CEO of ConcertAI. “Providing biopharma collaborators with access to integrated data of this depth and scale will help accelerate new medicines needed by patients with cancer, especially those with few available targeted therapy options.”